Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. ESSA Pharma’s rating score has declined by 67% in the last 90 days as a result of a number of analysts’ ratings changes.

Brokers have set a twelve-month consensus price objective of $5.10 for the company and are forecasting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 159 out of 265 based on the ratings given to related companies.

A number of research analysts recently weighed in on EPIX shares. Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Monday, September 11th. Bloom Burton lowered shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Finally, Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a research note on Thursday, August 3rd.

Shares of ESSA Pharma (NASDAQ EPIX) opened at 0.28 on Monday. ESSA Pharma has a 52 week low of $0.25 and a 52 week high of $3.59. The company has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.29. The company’s market capitalization is $8.15 million.

WARNING: “Zacks: ESSA Pharma Inc. (EPIX) Receives Average Rating of “Buy” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.